Dr. Wen Wang

Dr. Wen Wang,   Chief Executive Officer

Dr. Wang joined IASO Biotherapeutics in March 2020, and is currently the company's Chief Executive Officer.Dr. Wang graduated from Anhui Medical University with a Bachelor of Medicine (B.M.) degree. He was orthopedic resident doctor and attending physician in Shanghai TCM Integrated Hospital. Dr. Wang subsequently obtained Master of Medicine (M.M.) and Medical Doctor (M.D.) degrees from Tongji University, as well as doctorate in molecular biology (Ph.D) from University of Aberdeen. He was a post-doctoral fellow in the University of Connecticut Health Center, during which time he published over 20 SCI essays on cell therapy in leading publications like Clinical Cancer Research and Blood.

Dr. Wang joined the industry in 2013, having worked in Cellular Biomedicine Group (NASDAQ: CBMG), JW Therapeutics (SEHK: 02126), and Simecere Pharmaceutical Group (SEHK: 02096) as Medical Director, Senior Director of Clinical Development and Executive Director of Clinical Development respectively. Dr. Wang has had more than 10 years of experience in cell therapy since 2006. As a key member of the project team he participated in the company’s successful application of clinical test for CAR-T, the first targeted CD19 drug in China. He was appointed Chief Medical Officer of IASO Biotherapeutics in March 2020, leading the clinical development team in CT103A clinical test project. In April 2021 Dr. Wang was appointed Chief Executive Officer and took charge of the company’s day-to-day operation and management.